Hepatitis B DNA10^3, i.e., a quantitative hepatitis B DNA test value of three times ten, suggests that the hepatitis B virus NDA is positive, and whether to treat or not should be considered in the light of the actual situation of the test subject. For hepatitis B virus NDA-positive patients, antiviral treatment with nucleotide analogs such as interferon or entecavir is currently recommended in clinical practice. The indications are: 1. Accompanied by persistent elevation of biochemical glutamate alanyltransferase and exclusion of other causes of this enzyme abnormality. 2. or when evidence of hepatic fibrosis or cirrhosis is present. 3. or when age is greater than 30 years with a family history of cirrhosis or hepatocellular carcinoma. 4. Or when non-invasive diagnosis of liver fibrosis or histologic examination of the liver suggests evidence of hepatitis or liver fibrosis. 5. Or when extrahepatic manifestations of hepatitis B virus infection are present. There are no definitive treatment recommendations for hepatitis B virus NDA-positive individuals who do not have the above conditions. Hepatitis B virus NDA-positive patients are recommended to seek prompt medical treatment and complete other hepatitis B related tests to assess the need for treatment in order to avoid delaying the condition, and the above medications should be reasonably applied under the guidance of a doctor, to avoid the adverse effects caused by self-medication.